the slide continues, page-29

mav,
my initial thoughts. When thinking about a retail CR from the companies POV:
1) too much time and effort which detracts from producing the drugs. Simply not enough manpower = cost
2) cost of raising money in retail (lawyers, brokers etc) is rediculous.
3) risk of falling flat at the end of the day.

The real weights now rest on if they can get some things done and proved by the time the need more cap in 12 - 16 months. Be it through results or licencing. The market should allow us to have a go close to 3c too though, they usually make sure of that.

Sol